Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM5 | P08912 | 1/20 | 0.40 |
| ▸ | ABL1 | P00519 | 3/20 | 0.38 |
| ▸ | BCR | P11274 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.36 |
| ▸ | FLT3 | P36888 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.35 |
| ▸ | NTRK2 | Q16620 | 2/20 | 0.35 |
| ▸ | IRAK4 | Q9NWZ3 | 4/20 | 0.35 |
| ▸ | IRAK1 | P51617 | 3/20 | 0.35 |
| ▸ | CNR2 | P34972 | 2/20 | 0.34 |
| ▸ | CSF1R | P07333 | 1/20 | 0.34 |
| ▸ | ACP1 | P24666 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31044854 | 0.90 | KCNH2 (0.41) | KCNH2FLT3CYP3A4BRD4CNR2 | |
| SCHEMBL31044816 | 0.88 | KCNH2 (0.36) | KCNH2FLT3CYP3A4BRD4CNR2 | |
| SCHEMBL31044882 | 0.87 | FLT3 (0.44) | KCNH2FLT3CYP3A4CNR2ACP1 | |
| SCHEMBL31045183 | 0.86 | FLT3 (0.45) | KCNH2FLT3CYP3A4CNR2ACP1 | |
| SCHEMBL31045128 | 0.86 | KCNH2 (0.36) | KCNH2FLT3CYP3A4BRD4CNR2 | |
| SCHEMBL31045158 | 0.85 | BRD4 (0.37) | ABL1BCRKCNH2FLT3CYP3A4 | |
| SCHEMBL31045334 | 0.85 | KCNH2 (0.36) | ABL1KCNH2FLT3CYP3A4BRD4 | |
| SCHEMBL31045081 | 0.85 | GBA1 (0.45) | IRAK4IRAK1 | |
| SCHEMBL31044788 | 0.85 | KCNH2 (0.37) | ABL1KCNH2FLT3CYP3A4BRD4 | |
| SCHEMBL31044828 | 0.85 | CNR2 (0.39) | ABL1BCRKCNH2FLT3CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240279236-A1 | COMPOUNDS AND METHODS OF TREATING TUBERCULOSIS | FIMBRION THERAPEUTICS, INC. (US) | 2024-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240279236-A1 | COMPOUNDS AND METHODS OF TREATING TUBERCULOSIS | G6PD, SDHA, NQO1 | CHRM5 1363/4885ABL1 772/4885BCR 2539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.